Commentary & Perspectives

The Role of Human Leukocyte Antigens in Reducing Lung Cancer Risk

With findings that human leukocyte antigen-II (HLA-II) heterozygosity is associated with reduced risk of developing lung cancer, with particular benefits to smokers, Mount Sinai researchers add evidence to the theory of the immune system's protective function against cancer.

  • by

  • February 5, 2025

  • 1 min

Share

5 Key Takeaways

  • 1

    HLA-II heterozygosity linked to lower lung cancer risk.

  • 2

    Protective role is significant for smokers.

  • 3

    Study conducted by Mount Sinai researchers.

  • 4

    Findings support immune system's significance in cancer development.

  • 5

    Genetic factors are crucial in understanding lung cancer risk.

Related Content

Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer

The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy.

  • by

  • November 20, 2025

  • 3 min
Dana-Farber Research News 9.01.2024

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 1 through August 15.

  • by

  • September 1, 2024

  • 32 min
Decline in Lung Cancer Deaths Is Linked to Increased Screening

A recent, substantial decline in lung cancer deaths is associated with earlier diagnosis of lung cancer than in the past, a new study shows.

  • by

  • March 21, 2022

  • 1 min